N-甲基-2-噻吩甲胺 | 58255-18-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-甲基-2-噻吩甲胺
• 英文名称: N-methyl-1-(thiophen-2-yl)methanamine
• 英文别名: N-methyl-1-thiophen-2-ylmethanamine
• CAS: 58255-18-8
• 化学式: C₆H₉NS
• mdl: MFCD04625435
• 分子量: 127.21
• InChiKey: TTXJMSRLGMWEJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  75-80 °C(Press: 4 Torr)
• 密度：
  1.055±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与水接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R22
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Methyl-(thiophen-2-yl)methylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Methyl-(thiophen-2-yl)methylamine
CAS number: 58255-18-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9NS
Molecular weight: 127.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-甲基-2-噻吩甲胺 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.33h， 以68%的产率得到2-(adamantan-1-yl)-N-methyl-N-(thiophen-2-ylmethyl)acetamide
  参考文献：
  名称：

  WO2006/100502

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氯甲基噻吩 在 乙醇 、 甲胺 作用下， 生成 N-甲基-2-噻吩甲胺
  参考文献：
  名称：

  α-Thienylaminoalkanes

  摘要：

  DOI：

  10.1021/ja01255a001
• 作为试剂：
  描述：

  苯甲基苯胺 、 甘油 在 N-甲基-2-噻吩甲胺 、 tris(triphenylphosphine)ruthenium(II) chloride 、 1,1′-二(二环己基膦)二茂铁 、 potassium tert-butylate 作用下， 以 1,4-二氧六环 为溶剂， 反应 20.0h， 以76%的产率得到2-[苄基(苯基)氨基]-乙醇
  参考文献：
  名称：

  钌催化的粗甘油的可切换N-羟乙基化和N-乙酰化。

  摘要：

  通过氢借入方法实现了多元醇（例如粗甘油）对胺的N-羟乙基化或N-乙酰化的高效Ru催化选择性CC或CO键裂解。各种胺以中等至优异的产率转化为所需的氨基醇/酮，为从可再生原料生产含氧药物和精细化学品开辟了新途径。使用含有双膦/噻吩基甲胺配体的新型氧化还原活性催化剂可使该氢借用体系在碱性和酸性条件下选择性地操作。

  DOI：

  10.1002/cssc.201903151

文献信息

• Tetracoordinate borates as catalysts for reductive formylation of amines with carbon dioxide
  作者：Xiaolin Jiang、Zijun Huang、Mohamed Makha、Chen-Xia Du、Dongmei Zhao、Fang Wang、Yuehui Li

  DOI：10.1039/d0gc01741h

  日期：——

  We report sodium trihydroxyaryl borates as the first robust tetracoordinate organoboron catalysts for reductive functionalization of CO2. These catalysts, easily synthesized from condensing boronic acids with metal hydroxides, activate main group element–hydrogen (E–H) bonds efficiently. In contrast to BX3 type boranes, boronic acids and metal-BAr4 salts, under transition metal-free conditions, sodium

  我们报告三羟基芳基硼酸钠作为第一个坚固的四配位有机硼催化剂，用于CO 2的还原功能化。这些催化剂很容易从硼酸与金属氢氧化物的缩合反应中合成，可以有效地活化主族元素氢键。与BX 3型硼烷，硼酸和金属-BAr 4盐相比，在无过渡金属的条件下，三羟基芳基硼酸钠对各种胺（包括带有官能团的胺）表现出较高的还原性N-甲酰化反应性（106例）例如酯，烯烃，羟基，氰基，硝基，卤素，MeS–，醚基等。催化具有挑战性的吡啶胺的甲酰化反应的性能过高，为使用传统的甲酰化试剂提供了一种有前途的替代方法。机理研究支持将静电相互作用作为Si / B–H活化的关键，从而使碱金属硼酸盐成为用于CO 2加氢硼化，加氢硅烷化和还原甲酰化/甲基化的通用催化剂。
• Development of a Simple and Efficient Solution-Phase Parallel Synthesis of Flexible Non-Steroidal Estradiol Mimics
  作者：Guy Djigoue、Rene Maltais、Donald Poirier

  DOI：10.2174/1386207317666140915125620

  日期：2014.11.7

  An efficient parallel synthesis was designed to provide libraries of estradiol mimics that can potentially interact with different biological targets associated with estradiol-related diseases. Two libraries of 75 members each were synthesized around a non-steroidal core by adding three levels of molecular diversity. Hydroxybenzaldehydes (1st level of diversity), protected as a methoxymethyl ether

  设计了一种有效的平行合成方法，以提供可能与与雌二醇相关疾病相关的不同生物靶标相互作用的雌二醇模拟物文库。通过添加三个水平的分子多样性，围绕非甾体核心合成了两个75个成员的文库。被保护为甲氧基甲基醚的羟基苯甲醛（第1级多样性）在还原胺化条件下首先与伯胺（第2级多样性）反应。接下来，所得仲胺与4-溴-1,2-环氧丁烷反应，以提供作为第三级多样性的前体的环氧化物衍生物。然后使用各种亲核试剂打开每个环氧化物。
• 4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS
  申请人：Dos Santos Victor

  公开号：US20070021609A1

  公开（公告）日：2007-01-25

  The invention relates to substituted (4-phenylpiperazin-1-yl)acylpiperidine derivatives of formula (I) in the form of a base or an addition salt with an acid, and also in the form of a hydrate or solvate, and their preparation process and therapeutic application.

  这项发明涉及以碱或酸的加成盐形式存在的取代(4-苯基哌嗪-1-基)酰基哌啶衍生物（I）以及以水合物或溶剂合物形式存在的这些衍生物，以及它们的制备过程和治疗应用。
• CHEMICAL COMPOUNDS
  申请人：Deng Jianghe

  公开号：US20090143372A1

  公开（公告）日：2009-06-04

  The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型吲哚羧酰胺衍生物。具体而言，该发明涉及符合以下式I的化合物： 其中R1、R2、R3、U和V如下定义，并且其药学上可接受的盐。该发明的化合物是IKK2的抑制剂，可用于治疗与不当IKK2（也称为IKKβ）活性相关的疾病，如类风湿性关节炎、哮喘和慢性阻塞性肺病（COPD）。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制IKK2活性和治疗相关疾病的方法。
• Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome
  作者：Yan Ren、Yaning Su、Liming Sun、Sudan He、Lingjun Meng、Daohong Liao、Xiao Liu、Yongfen Ma、Chunyan Liu、Sisi Li、Hanying Ruan、Xiaoguang Lei、Xiaodong Wang、Zhiyuan Zhang

  DOI：10.1021/acs.jmedchem.6b01196

  日期：2017.2.9

  role in driving inflammation and disease pathology, cell necrosis has gradually been verified as a promising therapeutic target for treating atherosclerosis, systemic inflammatory response syndrome (SIRS), and ischemia injury, among other diseases. Most necrosis inhibitors targeting receptor-interacting protein 1 (RIP1) still require further optimization because of weak potency or poor metabolic stability

  基于其在驱动炎症和疾病病理学中的重要作用，细胞坏死已逐渐被证实是治疗动脉粥样硬化，全身性炎症反应综合征（SIRS）和缺血性损伤等疾病的有前途的治疗靶标。由于效价弱或代谢稳定性差，大多数靶向受体相互作用蛋白1（RIP1）的坏死抑制剂仍需要进一步优化。我们进行了表型筛选，并确定了具有新型酰胺结构的微摩尔分子。药物化学努力产生了高度有效的，选择性的和代谢稳定的候选药物，化合物56（RIPA -56）。生化研究和分子对接表明，RIP1是这一新的III型激酶抑制剂新系列的直接靶标。在SIRS小鼠疾病模型中，有56种有效降低了肿瘤坏死因子α（TNFα）诱导的死亡率和多器官损伤。与已知的RIP1抑制剂相比，56在人和鼠细胞中均有效，在体内更稳定，并且在动物模型研究中有效。